Therapeutic strategies for COVID-19: progress and lessons learned

G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Innate immune evasion strategies of SARS-CoV-2

JM Minkoff, B tenOever - Nature Reviews Microbiology, 2023 - nature.com
Abstract SARS-CoV-2, the virus responsible for the COVID-19 pandemic, has been
associated with substantial global morbidity and mortality. Despite a tropism that is largely …

A guide to immunotherapy for COVID-19

FL van de Veerdonk, E Giamarellos-Bourboulis… - Nature medicine, 2022 - nature.com
Immune dysregulation is an important component of the pathophysiology of COVID-19. A
large body of literature has reported the effect of immune-based therapies in patients with …

[HTML][HTML] Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo …

VC Marconi, AV Ramanan, S de Bono… - The lancet Respiratory …, 2021 - thelancet.com
Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-
inflammatory properties. This study evaluates the efficacy and safety of baricitinib in …

[PDF][PDF] Therapeutics and COVID-19: living guideline, 14 July 2022

World Health Organization - 2022 - apps.who.int
As of May 2022, there have been over 524 million confirmed cases of COVID-19 (10). The
pandemic has thus far claimed approximately 6.2 million lives (10). Vaccination is having a …

The development of COVID-19 treatment

Y Yuan, B Jiao, L Qu, D Yang, R Liu - Frontiers in immunology, 2023 - frontiersin.org
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial

E Kyriazopoulou, G Poulakou, H Milionis, S Metallidis… - Nature medicine, 2021 - nature.com
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment

S Drożdżal, J Rosik, K Lechowicz, F Machaj… - Drug Resistance …, 2021 - Elsevier
The COVID-19 pandemic is one of the greatest threats to human health in the 21st century
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …

COVID-19 therapeutics: Challenges and directions for the future

PC Robinson, DFL Liew, HL Tanner… - Proceedings of the …, 2022 - National Acad Sciences
The emergence of SARS-CoV-2 triggering the COVID-19 pandemic ranks as arguably the
greatest medical emergency of the last century. COVID-19 has highlighted health disparities …

Host-directed immunotherapy of viral and bacterial infections: past, present and future

RS Wallis, A O'Garra, A Sher, A Wack - Nature Reviews Immunology, 2023 - nature.com
The advent of COVID-19 and the persistent threat of infectious diseases such as
tuberculosis, malaria, influenza and HIV/AIDS remind us of the marked impact that infections …